We are
Helius
Medical.

Helius is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

The Pioneers of Portable
Neurostimulation
Pushing treatment options to rehabilitate lost function into the future
Solutions Backed
by Science
Dedicating years of research to ensure safety and efficacy
Enhancing the
Human Experience
Empowering individuals with neurological disorders and traumatic brain injury (mmTBI) by increasing their independence and quality of life
Real Patients with
Real Results*
“PoNS Therapy™ enabled me to improve my walking. Some tasks seem easier, which make my daily life better.”
Helius Medical Technologies Logo

We are
Helius
Medical.

Helius is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

Our Origin

Helius’ origin stems from the early 1990s, and the pioneering work in neuroplasticity at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. This work led to the development of the investigational Portable Neuromodulation Stimulator (PoNS®), that delivers neurostimulation via the tongue, which has been shown in clinical studies to improve the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury.
Discover PoNS
Discover PoNS

Helius News

See All

Helius Medical Technologies to Present at LD Micro Invitational XIII 2023

NEWTOWN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief

May 25, 2023

Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day

NEWTOWN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (Nasdaq:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for gait deficits, is excited to announce its participation in the prestigious Consortium of Multiple Sclerosis Centers

May 24, 2023

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEWTOWN, Pa., May 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective May 18, 2023, its independent directors approved an equity award under Helius’ 2021

May 19, 2023

Helius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results

-- Company to host call at 4:30pm today -- NEWTOWN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today

May 11, 2023

See All

Careers at Helius Medical

At Helius, you can have a positive impact on the lives of millions of people around the globe who rely on our innovations for their recovery. Helius brings together the world’s best talent to succeed in our ongoing mission. Together, we work passionately to develop and deliver easy-to-use technology for neurological wellness. If you want to join us in our mission, we want to hear from you.

View Open Positions